Muhanna N, Chan H, Townson JL, Jin CS, Ding L, Valic M, Douglas CM, MacLaughlin CM, Chen J, Zheng G, Irish JC Endocrine-related cancer, 2019 DOI: 10.1530/ERC-19-0258 The incidence of differentiated thyroid cancer has increased significantly during the last several decades. Surgical resection is the primary treatment for thyroid cancerContinue Reading
Cruz W, Huang H, Barber B, Pasini E, Ding L, Zheng G, Chen J, Bhat M Hepatology Communications, 2020 DOI: 10.1002/hep4.1493 Patients with advanced hepatocellular carcinoma (HCC) are often unable to tolerate chemotherapy due to liver dysfunction in the setting of cirrhosis. We investigate high‐density lipoprotein (HDL)‐mimicking peptide phospholipid scaffoldContinue Reading
Overchuk M, Zheng M, Rajora MA, Charron DM, Chen J & Zheng G ACS Nano, 2019 DOI: 10.1021/acsnano.9b00494 Lipoprotein mimetic nanostructures, which consist of an amphiphilic lipid shell, a hydrophobic core, and an apolipoprotein mimetic peptide, serve as a versatile platform for the design of drug delivery vehicles as wellContinue Reading
Harmatys K, Chen J, Charron DM, MacLaughlin CM & Zheng G Angewandte Chemie, 2018 DOI: 10.1002/ange.201803535 Biomimetics are reconstructions of natural systems in engineered forms to exploit their structural or functional properties. Current biomimetics for medical applications use a single biomimetic approach to imitate natural structures, which can be insufficientContinue Reading
Rajora MA, Ding L, Valic M, Jiang W, Overchuk M, Chen J & Zheng G Chemical Science, 2017 DOI: 10.1039/C7SC00732A The development of curative glioblastoma treatments and tumour-specific contrast agents that can overcome the blood–brain barrier (BBB) and infiltrative tumour morphology remains a challenge. Apolipoprotein E3 (apoE3) is a highContinue Reading
Charron DM, Chen J & Zheng G ChemNanoMat, 2016 Nanocarriers incorporating therapeutic and imaging agents within a single nanostructure are emerging tools for drug development and treatment planning. Additional information can be provided using activatable fluorescence that dynamically reports nanocarrier disruption and drug release. Dual-wavelength activation encodes a unique fluorescenceContinue Reading
Muhanna N, Cui L, Chan H, Burgess L, Jin CS, MacDonald TD, Huynh E, Wang F, Chen J, Irish JC & Zheng G Clinical Cancer Research, 2015 Purpose: The low survival rate of head-and-neck cancer (HNC) patients is attributable to late disease diagnosis and high recurrence rate. Current HNC stagingContinue Reading
Huang H, Cruz W, Chen J, Zheng G Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2015 DOI: 10.1002/wnan.1308 Synthetic lipoproteins represent a relevant tool for targeted delivery of biological/chemical agents (chemotherapeutics, siRNAs, photosensitizers, and imaging contrast agents) into various cell types. These nanoparticles offer a number of advantages for drugs deliveryContinue Reading
Cui L, Lin Q, Jin CS, Jiang W, Huang H, Ding L, Muhanna N, Irish JC, Wang F, Chen J & Zheng G ACS Nano, 2015 PEGylation (PEG) is the most commonly adopted strategy to prolong nanoparticles’ vascular circulation by mitigating the reticuloendothelial system uptake. However, there remain many concernsContinue Reading
Lin Q, Chen J, Zhang Z, Zheng G Nanomedicine, 2014 DOI: 10.2217/nnm.13.192 RNAi therapeutics are believed to be the future of personalized medicine and have shown promise in early clinical trials. However, many physiological barriers exist in the systemic delivery of siRNAs to the cytoplasm of targeted cells to performContinue Reading
